CHE CHE
Company Profile ↓Company Overview
CHE (CHE) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 27.1%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 27.0%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.53B (+65.3% YoY); net profit $265.24M.
- Trailing 12 Months Year-on-year growth — revenue +65.2%, earnings -12.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.8%, profit CAGR 8.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.75% |
| 1 Year: | 65.25% |
Compounded Profit Growth
| 5 Years: | 8.40% |
| 1 Year: | -12.17% |
Stock Price Performance
| 1 Year: | +29.80% |
| 6 Months: | +26.51% |
| 3 Months: | +28.00% |
| 1 Month: | +12.60% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)76.75 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 27.1%.
- Healthy ROCE of 27.0%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- RSI at 77 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 315.79M | 311.94M | 317.41M | 299.19M | 297.78M | 296.54M | 310.48M | 320.86M | 333.73M | 354.01M | 374.56M | 391.41M | - | - | - | - | - |
| Operating Income | 25.89M | 29.21M | 36.65M | 41.52M | 40.21M | 40.57M | 44.60M | 50.13M | 44.39M | 38.36M | 42.87M | 41.45M | -38.95M | 54.00M | 56.40M | 58.14M | 61.71M | 49.47M | 65.53M | 64.93M | 79.36M | 92.76M | 74.31M | 80.44M | 71.70M | 92.87M | 89.37M | 91.94M | 80.86M | 72.82M | 69.51M | 86.85M | 72.33M | 88.12M | 92.16M | 94.76M | 68.08M | 74.75M | 84.58M | 89.20M |
| Net Income | 14.61M | 17.43M | 20.57M | 24.36M | 24.59M | 24.54M | 26.98M | 28.83M | 24.84M | 24.89M | 26.83M | 29.84M | -21.66M | 35.44M | 45.00M | 54.97M | 51.25M | 44.67M | 50.73M | 58.95M | 55.89M | 82.10M | 67.72M | 65.40M | 56.52M | 72.00M | 64.17M | 66.46M | 56.87M | 54.12M | 53.38M | 74.96M | 65.02M | 70.89M | 75.78M | 71.76M | 52.49M | 64.24M | 66.30M | 67.70M |
| Diluted EPS | 0.77 | 0.94 | 1.12 | 1.36 | 1.39 | 1.40 | 1.55 | 1.65 | 1.45 | 1.48 | 1.62 | 1.78 | -1.35 | 2.13 | 2.66 | 3.27 | 3.06 | 2.70 | 3.08 | 3.56 | 3.38 | 5.01 | 4.14 | 4.01 | 3.51 | 4.55 | 4.22 | 4.40 | 3.78 | 3.58 | 3.51 | 4.93 | 4.24 | 4.65 | 5.00 | 4.86 | 3.57 | 4.46 | 4.84 | 5.13 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.15B | 1.19B | 1.28B | 1.36B | 1.43B | 1.41B | 1.46B | 1.54B | 1.58B | 1.67B | 1.20B | 1.28B | 1.33B | 1.26B | 1.20B | 1.32B | 1.53B | 2.53B |
| Operating Income | 132.86M | 126.34M | 143.52M | 153.73M | 156.42M | 133.39M | 168.42M | 184.46M | 178.75M | 113.03M | 243.63M | 257.38M | 389.68M | 343.04M | 343.50M | 340.57M | 366.49M | 338.25M |
| Net Income | 67.28M | 73.78M | 81.83M | 85.98M | 89.30M | 77.23M | 99.32M | 110.27M | 108.74M | 98.18M | 205.54M | 219.92M | 319.47M | 268.55M | 249.62M | 272.51M | 302.00M | 265.24M |
| Diluted EPS | 2.88 | 3.24 | 3.55 | 4.10 | 4.62 | 4.16 | 5.57 | 6.33 | 6.48 | 5.86 | 12.23 | 13.31 | 19.48 | 16.85 | 16.53 | 17.93 | 19.89 | 18.34 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 819.47M | 830.16M | 795.90M | 859.63M | 893.70M | 859.93M | 852.33M | 880.06M | 920.03M | 975.53M | 1.27B | 1.43B | 1.34B | 1.44B | 1.67B | 1.67B | 1.54B |
| Total Equity | 395.80M | 396.83M | 477.16M | 462.05M | 413.68M | 453.29M | 448.89M | 451.36M | 513.25M | 524.10M | 540.35M | 591.33M | 726.61M | 901.20M | 623.27M | 798.72M | 1.11B | 1.12B | 979.40M |
| Cash & Equivalents | 4.99M | 3.63M | 112.42M | 49.92M | 38.08M | 69.53M | 84.42M | 14.13M | 14.73M | 15.31M | 11.12M | 4.83M | 6.16M | 162.68M | 32.90M | 74.13M | 263.96M | 178.35M | 74.52M |
| Long Term Debt | - | - | 152.13M | 159.21M | 166.78M | 174.89M | 183.56M | 141.25M | 83.75M | 100.00M | 91.20M | 89.20M | 90.00M | - | 185.00M | 92.50M | - | - | - |
| Total Liabilities | - | - | 342.31M | 368.11M | 382.22M | 406.33M | 444.81M | 408.58M | 339.07M | 355.96M | 379.67M | 384.19M | 541.71M | 533.71M | 719.45M | 643.30M | 560.22M | 549.58M | 558.78M |
| Current Liabilities | - | - | 136.08M | 149.34M | 145.40M | 156.82M | 363.99M | 175.55M | 171.34M | 171.83M | 193.52M | 191.67M | 262.22M | 299.11M | 302.40M | 297.20M | 312.05M | 285.69M | 287.13M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 112.08M | 160.83M | 86.01M | 174.34M | 131.77M | - | - | 171.50M | 135.39M | 162.50M | 287.14M | 301.25M | 489.29M | - | 309.89M | 330.30M | 417.50M | 388.27M |
| Investing Cash Flow | -28.63M | -22.84M | -35.70M | -34.11M | -40.68M | -31.35M | - | -50.32M | -39.86M | -67.61M | -105.22M | -190.76M | -61.56M | - | -59.40M | -60.64M | -143.91M | -59.34M |
| Financing Cash Flow | -84.82M | -29.20M | -112.81M | -152.06M | -59.63M | -104.61M | - | -120.59M | -94.95M | -99.08M | -188.20M | -109.16M | -271.21M | - | -209.25M | -79.83M | -359.19M | -432.77M |
| Capital Expenditure | -26.09M | -21.50M | -25.64M | -29.59M | -35.25M | -29.32M | -43.57M | -44.13M | -39.77M | -64.30M | -52.87M | -53.02M | -58.83M | - | -57.33M | -56.85M | -49.53M | -62.80M |
| Free Cash Flow | 85.99M | 139.34M | 60.37M | 144.75M | 96.52M | - | - | 127.36M | 95.62M | 98.19M | 234.27M | 248.23M | 430.46M | - | 252.56M | 273.44M | 367.97M | 325.48M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 41.23M | 189.83M | -85.61M | -103.83M |
| Share Buybacks | 67.12M | 742.00K | 109.33M | 143.97M | 60.62M | 92.91M | 110.02M | 59.32M | 102.31M | 94.64M | 158.88M | 92.63M | 175.59M | 576.04M | 114.52M | 67.70M | 361.39M | 431.50M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 11.6% | 10.6% | 11.2% | 11.3% | 10.9% | 9.4% | 11.6% | 12.0% | 11.3% | 6.8% | 20.3% | 20.1% | 29.2% | 27.2% | 28.6% | 25.9% | 23.9% | 13.4% |
| Net Margin % | 5.9% | 6.2% | 6.4% | 6.3% | 6.2% | 5.5% | 6.8% | 7.1% | 6.9% | 5.9% | 17.2% | 17.2% | 23.9% | 21.3% | 20.8% | 20.7% | 19.7% | 10.5% |
| ROE % | 17.0% | 15.5% | 17.7% | 20.8% | 19.7% | 17.2% | 22.0% | 21.5% | 20.7% | 18.2% | 34.8% | 30.3% | 35.4% | 43.1% | 31.3% | 24.6% | 27.0% | 27.1% |
| ROCE % | - | 18.5% | 21.1% | 23.6% | 22.3% | 25.2% | 24.6% | 27.1% | 25.2% | 15.6% | 31.1% | 25.6% | 34.3% | 33.0% | 30.0% | 25.1% | 26.5% | 27.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CHE
Amundi Raises Stock Position in Chemed Corporation $CHE - MarketBeat
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOUmdMcjNkajBuQmJ2X0tRWEdlUGRuQlI1aHBtYmZwRl9iaHBnMzZ4WVBIa0ROeWFsVmU1a2xobEx3SmhOMHlOWFdUZ3ZrdE0tcXc1S0oxdmwxVG5KTEZzWms2SGZrR0p0Q1RFN2RXRUZmZXFUZ1JLbFJNbUxtSXVSMW1pR0JmalNQRjVwSz…
Trend Tracker for (CHE.DB.E) (CHE.DB.E:CA) - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPWk5LSmtveE5aSVJjMkJhbnNWUkpHYkNnOTZDTXRTLWxXVmx1U3RJYWdmQTFha21ENy1YLUVvOS1NbnhmMUJKWTNzSG9Wa0x3Tl9JZUZ4MnNhVFdMRFVsbmJDa0VrMTdyY2JFRmNVS1hwVWt1LURaQ0hKODhWSkFhc3pUNDBuM085ejlR?o…
Chemed Corporation: Why A Spin-Off Could Unlock Its Hidden Value (NYSE:CHE) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQaWFQUFNFS1pnUlBFRnZqaTQzWVJfMThLdkt2VGRxdUhDLW44RXZ1eHNEOE5Ga2kzZWdRcy05U1pkaE5mZ3RiM0NKaWFxZ1ZCN2UybmpmeDNwWmJyQ0RxNWxEV0FSMGh3aTlmTVkzRllOSmk5bm5FYzBsSkFsZ1RXaE1IbFZJMExVUVlLeS…
Have Insiders Sold Chemed Shares Recently? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNX2JZQ2JLWEtfWGgzSHJETjVaeUJFV3JNT1VGUE1HNHVWZVNRM1o3aGlNVi1QQ3dPbGNvN0VEV2VCbkJGT054UXJPcVdJSy0zbzRwLVFCZm5VcXVUVjI4Tm1WZXBzcjNNYkptX3g3dWM4SW4zNXg2UFdkM3Y4cjR5QnhjZTRIT05IalpPSX…
Chemed (NYSE: CHE) director sells 190 shares at $532 in open trade - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOSTJ5dDluXzNSMEU2OG5HLWJuTGd6YTdJR18wUWRoVE9pSlJRNVFOejdwRzVPRFpWVjJVNzBDS0VfY21lNHFPd01pLTRWTUpaSVlyVWhpUFNYNmtvWUV6WUE3dGtXSjNteFVhNUtnRFBKQ1ZCanNkRzV2ZUEwbF9DVHcwbW85TWdUakNOek…
Chemed (CHE) Deepens Buybacks as Activist Pressure Mounts – What Does This Say About Strategy? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOWFltaGdYajUySUE3SWx3eEdEMW4xZGQ2RmhJdU54STNNbUZ3d2t0MGowWnBZUkNTQWxLZW1MU3Via0dSdUZtWUUwT19IRjdNemw0S25mbWhqRnZWM2ZQZzRqX3EzYzl5UVBlX2hXeFY1MmRJS2FFVjlWcjdYTThOb0pIcG9KekxQUnRWOF…
CHE — Frequently Asked Questions
What is the current share price of CHE?
As of 2026-08-05 17:25 PDT, CHE trades at $546.51 on NASDAQ/NYSE. Its 52-week range is $368.09 to $546.51.
What is the P/E ratio of CHE?
CHE trades at a trailing price-to-earnings (P/E) ratio of 29.80.
What is the return on equity (ROE) of CHE?
CHE has a return on equity (ROE) of 27.08%. Its return on capital employed (ROCE) is 27.04%.
Is CHE a good stock to buy?
This page provides a data-driven analysis of CHE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.